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Abstract: A precision health initiative was implemented across a multi-hospital health system,
wherein a panel of genetic variants was tested and utilized in the clinical care of chronic kidney
disease (CKD) patients. Pharmacogenomic predictors of antihypertensive response and genomic
predictors of CKD were provided to clinicians caring for nephrology patients. To assess clinician
knowledge, attitudes, and willingness to act on genetic testing results, a Likert-scale survey was sent
to and self-administered by these nephrology providers (N = 76). Most respondents agreed that
utilizing pharmacogenomic-guided antihypertensive prescribing is valuable (4.0 ± 0.7 on a scale of 1
to 5, where 5 indicates strong agreement). However, the respondents also expressed reluctance to use
genetic testing for CKD risk stratification due to a perceived lack of supporting evidence (3.2 ± 0.9).
Exploratory sub-group analyses associated this reluctance with negative responses to both knowledge
and attitude discipline questions, thus suggesting reduced exposure to and comfort with genetic
information. Given the evolving nature of genomic implementation in clinical care, further education
is warranted to help overcome these perception barriers.
Keywords: chronic kidney disease (CKD), hypertension (HTN), genetic testing; pharmacogenomics;
APOL1
1. Introduction
Chronic kidney disease (CKD) and essential hypertension (HTN) affect roughly 15% and 30%
of the general American population respectively [1,2]. While CKD is often concomitant with the
occurrence of HTN, not all individuals with HTN develop CKD. The gap in knowledge regarding
the causes of CKD and its association with other medical conditions is now being filled by emerging
data on genetic determinants (which may be predictive of disease progression or therapeutic drug
response) [3,4]. The perceived knowledge of, attitudes toward, and willingness to act on this genetic
information are unknown among clinicians caring for nephrology patients. This study seeks to assess
provider’s survey responses prior to the implementation of a broad genetic testing protocol.
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Single nucleotide polymorphisms (SNPs) are the most common type of genetic variation and occur
when there is a mutation at a single base pair. The etiologies of many diseases have been attributed to
SNPs, and their identification has contributed to the pathophysiology of different types of CKD [3,5].
For example, the presence of susceptibility variants in particular gene loci (e.g., the loci of UMOD and
APOL1), may increase the risk of CKD and increase the possibility of end stage renal disease (ESRD) in
specific populations [6,7]. Namely, APOL1 polymorphisms, which are found as homozygous recessive
risk alleles in approximately 10% of the African American population, are now recognized as risk
factors that increase the progression of hypertensive and glomerular kidney diseases [7]. Additionally,
other genetic predictors such as variations in UMOD, SHROOM3, PDILT, and others, have been
uncovered in the CKDgen consortium [8]. Without the identification of these variants, many cases of
CKD would still be classified as secondary to hypertension or an unknown etiology.
SNPs also contribute to an individual’s pharmacogenomic profile, and thus influence overall drug
effectiveness, therapeutic index, adverse drug reactions, and other kinetic processes [9–11]. The Clinical
Pharmacogenetics Implementation Consortium (CPIC) has reported approximately 350 drug-gene
pairs (110 of which are identified as actionable pairs (this indicates the SNP requires altered drug
selection or dosing)); however antihypertensive drug-gene pairs have not been endorsed yet [11,12].
Similarly, the Dutch Pharmacogenomic Working Group (DPWG) has recommended only one actionable
antihypertensive drug-gene pair (i.e., CYP2D6 and metoprolol) [13]. A lack of substantial support for
antihypertensive pharmacogenomics has resulted in slower clinical implementation efforts that lag
behind those of other drug-gene pairs [11].
In an effort to improve drug efficacy and reduce adverse events, clinical genetic and pharmacogenomic
testing utilization has been promoted by physicians and researchers in a multi-hospital health system
consisting of a university hospital and a county safety-net hospital. Within this health system, broad
based panel testing was previously implemented for many CPIC level drug-gene pairs [14]. In 2018,
implementation was expanded to test for variants in genes related to CKD progression, as well as
pharmacogenetic variants predictive of antihypertensive agent efficacy [15]. Practitioners caring for
patients with kidney disease received a panel of results on 72 variants in 26 genes relevant to CKD and
hypertension pharmacogenomics. These results were uploaded to the health system’s electronic health
record (EHR). While the providers may use this testing to change their practice, all changes in clinical
care are at their behest.
In order to understand physician knowledge, attitude, and utilization of the genetic testing
platform, physicians were surveyed and their responses were analyzed. We hypothesized that
practitioners who cared for patients with renal disease would welcome the additional genetic data,
which could enable the refinement of diagnosis and selection of the most efficacious antihypertensive
agents. By performing a comparative analysis between survey question responses, an understanding
of the physician’s knowledge, attitudes, and propensity to act on genetic data can be evaluated [16].
The ensuing analysis illuminated the barriers of the translation of clinical genetic testing and
pharmacogenomics from research to everyday clinical practice.
2. Results
2.1. Implementation
Nephrologists practicing in a multi-hospital system, including a university and county safety-net
hospital system, were approached for assent to genotype their patients for variants predictive of
CKD and antihypertensive efficacy. The patients of assenting nephrologists were only genotyped
after providing informed consent during their outpatient clinic visits. In most cases, results were
provided to the clinician through the EHR within 2 weeks of the clinic visit. A complete list of genes,
variants, and clinical phenotypes provided is included in Table 1. Evidence for these variants has been
previously reviewed [11,17]. Variants with abundant evidence relevant to cardiovascular drugs were
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also included in the panel. The nephrologists and trainees completed baseline surveys prior to the
genotyping of their first patient.
Table 1. Phenotype—Genotype Interactions tested.
Gene Variants Tested Relevant Phenotype
ADRB1 rs1801252, rs1801253 Beta-Blocker Efficacy
APOL1 rs73885319, rs60910145, rs71785313 Risk of CKD
CYP2C19 rs4244285, rs4986893, rs28399504, rs72552267, rs41291556,rs6413438, rs12248560 Clopidogrel Efficacy
CYP2C9 rs1799853, rs1057910, rs28371686, rs9332131, rs7900194,rs28371685 Losartan Efficacy
CYP2D6
rs16947, rs1135840, rs35742686, rs3892097, rs1065852,
rs5030655, rs5030867, rs5030865(A), rs5030656, rs1065852,
rs1135840, rs5030865(T), rs28371706, rs61736512,
rs59421388, rs1135840, rs28371725
Metoprolol Efficacy
CYP3A4 rs55785340, rs35599367 Tacrolimus Dosing
CYP3A5 rs776746, rs10264272, rs41303343 Tacrolimus Dosing
F7 rs6046 Amlodipine Efficacy
FGF5/SH2B3/EBF1 rs1458038, rs3184504, rs4551053 Thiazide Efficacy
GRK4 rs2960306, rs1024323 Beta-Blocker Efficacy
LINC00923 rs653747 Risk of CKD
LOC105369332 rs2282538 Risk of CKD
NAT2 rs1801279, rs1801280, rs1799930, rs1799931 Hydralazine Efficacy
NEDD4L rs4149601 Diuretic Efficacy
NPHS1 rs3814995 Angiotensin receptorblocker efficacy
SLC3A2 rs489381 Risk of CKD
SLCO1B1 rs4149056, rs4149015 Simvastatin Dosing
SHROOM3 rs17319721, rs4371638, rs13146355 Risk of CKD
TPMT rs1800462, rs1800460 and rs1142345, rs1800460, rs1142345,rs1800584 Azathioprine Dosing
UMOD/PDILT rs4293393, rs12917707, rs11864909 Risk of CKD
VASP rs10995 Thiazide Efficacy
VKORC1 rs9923231 Warfarin Sensitivity
YEATS4 rs7297610 Thiazide Efficacy
CKD: Chronic kidney disease.
2.2. Demographics
A total of 76 respondents completed or partially completed the survey, of whom 51% (N = 39) were
nephrologists and 49% (N = 37) were trainee residents or fellows who were rotating on a nephrology
service. The survey response rate was 81%. Of the 76 respondents, 95% (N = 72) completed the entirety
of the survey and 35% (N = 27) were female. The health care system of practice and the racial and
ethnic breakdowns of the participants are given in Table 2. A total of 26 providers within the university
health system and county safety-net hospital system received pharmacogenomic and genetic testing
results for their patients. All surveys were completed prior to the implementation of genetic testing.
Life 2020, 10, 32 4 of 14
Table 2. Demographics of health care provider survey respondents and recipients.
Demographic Respondents (%)
Total N 76 (-)
Gender
Female 27 (35.5)
Male 47 (61.8)
Other or prefer not to answer 1 (1.3)
No response 1 (1.3)
Race
Black or African American 1 (1.3)
American Indian or Alaska Native 1 (1.3)
Asian 23 (30.3)
Hispanic or Latino 1 (1.3)
Native Hawaiian or Pacific Islander 0 (0)
White or Caucasian 42 (55.3)
Other or prefer not to answer 5 (6.6)
No response 3 (3.9)
Training
Trainee 37 (48.7)
Nephrologist 39 (51.3)
Other 0 (0)
Health System
County Safety Net Hospital 9 (11.8)
University Hospital 32 (42.1)
Affiliated University Hospital with private practice model 17 (22.4)
Pediatric Hospital 3 (3.9)
Veteran Affairs Hospital 7 (9.2)
Unknown 8 (10.5)
Percentages may not total 100% due to rounding. Trainees: fellows and residents; Nephrologists: nephrologists in
practice or outside an academic environment, nurse practitioner, physician assistant, or other clinician, academic
attending nephrologist (majority of time spent in clinical care), academic attending nephrologist (majority of time
spent in research, teaching, or administration); -, not applicable.
2.3. The Survey
Question category classification and the overall mean± standard deviation agreement responses are
illustrated in Table 3. Questions were stratified by discipline (i.e., Knowledge, Attitude, or Action) and
one of three discussion topic categories. These categories included clinician opinions on genetics overall
(General), genetic prediction of CKD progression (CKD), and genetic prediction of antihypertensive
response (HTN). Responses were scored on a Likert scale from 1 to 5, with 5 indicating strong agreement.
Table 3. Survey question conditions and disciplines.
Question Condition Discipline Mean (SD) Agreement
1. A patient’s genetic profile can influence
their risk of CKD progression CKD Knowledge 4.2 (0.6)
2. Genetic testing will help me to better
diagnose the cause of my patient’s CKD CKD Action 3.6 (0.8)
3. Patients and their families can benefit from
understanding genetic contributors to
their CKD.
CKD Attitude 4.0 (0.6)
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Table 3. Cont.
Question Condition Discipline Mean (SD) Agreement
4. Genetic testing of my CKD patients
provides information that may change my
therapeutic management of patients.
CKD Action 3.8 (0.8)
5. Genetic testing of my CKD patients
provides information that changes dialysis
preparation strategies in my patients.
CKD Action 3.3 (0.9)
6. Genetic testing for CKD provides
information that will help me delay or halt
the progression of CKD in my patients.
CKD Action 3.5 (0.8)
7. The presence of 2 APOL1 risk alleles in a
potential donor would impact the decision to
donate a kidney for transplantion.
CKD Action 3.8 (0.8)
8. The presence of 2 APOL1 risk alleles in a
patient would impact my management of
Focal Segmental Glomerulosclerosis (FSGS).
CKD Action 3.6 (0.7)
9. I personally review and discuss a family
history (taken by myself or a
physician-in-training/nurse/physician
extender) for every patient I meet in the
hospital or in a clinic.
General Attitude 4.1 (0.8)
10. Genetic testing is a valuable complement
to a detailed family history. General Knowledge 3.7 (0.7)
11. Discussing genetic testing results with
patients will lead to increased patient anxiety. General Attitude 3.1 (1.1)
12. Nephrologists should be trained to
interpret and counsel patients on genetic
variants that contribute to CKD.
CKD Attitude 4.1 (0.6)
13. Genetic counselors should be trained to
interpret and counsel patients on genetic
variants that contribute to CKD.
CKD Attitude 4.2 (0.6)
14. There is sufficient evidence to implement
genetic testing in patients with CKD. CKD Knowledge 3.2 (0.9)
15. The benefits of genetic testing outweigh
the risks to patients. General Knowledge 3.8 (0.7)
16. I feel comfortable discussing genetic test
results with patients. General Attitude 3.1 (1.1)
17. A discussion of genetic test results is too
time-consuming for a clinic encounter. General Attitude 3.3 (1.0)
18. Genetic testing may help me better treat
my patient’s hypertension. HTN Knowledge 3.8 (0.8)
19. A patient’s genetic profile can influence
their therapeutic response to
antihypertensives.
HTN Knowledge 4.0 (0.7)
20. Genetic testing of my HTN patients
provides information that may change the
antihypertensives that I prescribe.
HTN Action 3.8 (0.9)
21. Genetic testing of my HTN patients
provides information that may help me better
achieve the recommended blood
pressure goals.
HTN Action 3.7 (0.8)
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Table 3. Cont.
Question Condition Discipline Mean (SD) Agreement
22. Provided no contraindications exist, I
would follow the dosing suggestions of a
pharmacogenomic test for a NEW
prescription if the test indicated an alternate
medication or dose was appropriate.
HTN Action 4.0 (0.7)
23. Provided no contraindications exist, I
would change an EXISTING prescription, one
in which the patient had a stable response, in
order to follow the dosing suggestions of a
pharmacogenomic test if the test indicated an
alternate medication or dose was appropriate.
HTN Action 3.4 (0.9)
The averages and standard deviations were found within the context of one nonresponse for both questions 4 and 5.
CKD: Chronic Kidney Disease; HTN: Hypertension.
Across the entire cohort of respondents, practitioners agreed that a patient’s genetic profile can
influence CKD progression (Question 1 (Q1), 4.2 ± 0.6) and therapeutic response to antihypertensives
(Q19, 4.0 ± 0.7). While the majority of respondents agreed that genetic makeup influences CKD
progression and drug response, fewer respondents agreed there is sufficient evidence to implement
genetic testing in patients with CKD (Q14, 3.2 ± 0.9). Despite this discrepancy, the majority of
respondents agreed they would follow the dosing suggestions of a pharmacogenomic test for a new
prescription (Q22, 4.0 ± 0.7). The questions with the lowest level of agreement were among those with
the widest standard deviation of responses (Q11, Q16, and Q17). As such, practitioners were split as to
whether genetic testing would increase patient anxiety, their comfort level in discussing results, and
time limitations for holding such a discussion in clinic. Complete response comparisons are provided
in Supplemental Table S1.
2.4. General Knowledge and Attitude Toward Genetics
A sub-analysis of the main survey results sought to understand the impact of knowledge and
attitude on a clinician’s willingness to act on genetic data. Clinicians were more likely to agree
that genetic testing benefits outweigh the risks (Q15). Those who agreed that the benefits outweigh
the risks were also more likely to agree that the presence of two APOL1 risk alleles in one of their
Focal Segmental Glomerulosclerosis (FSGS) patients would affect their therapeutic management (Q8,
p = 0.006) and were more likely to agree that they would comply with the dosing suggestions of a
pharmacogenomic test for new prescriptions (Q22, p = 0.002). Those who believe that the benefits
outweigh the risks appear to be more willing to act on genetic data and comply with pharmacogenomic
dosing suggestions. Of the individuals who agreed the benefits outweighed risks, the data suggested
they are more willing to act on pharmacogenomic data than genetic testing data (Q4, p = 0.01, and Q8).
Figure 1A–C illustrates the responses to other questions stratified by response to question 15.
Clinicians relayed a split response in attitude when asked if they felt comfortable discussing
genetic results with their patients (Q16). Those who agreed and those who did not agree showed
differences in their willingness to act on genetic data. The majority of clinicians who agreed that they
felt comfortable discussing genetic results also agreed that genetic testing provides information that
may influence them to change the therapeutic management of their CKD patients (Q4, p = 0.003).
Clinicians who did not feel comfortable discussing results were proportionately less likely to agree that
genetic testing may impact their therapeutic strategy (Q4). Figure 1D–F suggest that after stratifying
clinicians by their comfort in discussing genetic results, the comfortable physicians were more likely to
act on the results.
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Figure 1. (A–C) Survey respondents who felt the benefits of genetic testing outweigh the risks (Q15) 
also agreed that (A) genetic testing of CKD patients provides information that may change therapeutic 
management (Q4, p = 0.013), (B) the presence of two APOL1 risk alleles in a patient would impact 
management of Focal Segmental Glomerulosclerosis (FSGS) (Q8, p = 0.0057), and (C) they would 
follow the dosing suggestions of a pharmacogenomic test for new prescriptions (Q22, p = 0.0018). (D–
F) The majority of survey respondents who agreed they feel comfortable discussing genetic results 
with patients (Q16) also agreed that (D) genetic testing of CKD patients may affect therapeutic 
management (Q4, p = 0.0031), (E) genetic testing complements a detailed family history (Q10, p = 
0.0010), and (F) a patient’s genetic profile can influence their therapeutic response to 
antihypertensives (Q19, p = 0.0038). Response colors are strongly agree (white), agree (light gray), 
neutral (medium gray), disagree (dark gray), and strongly disagree (black). 
2.5. Genetics Predictors of Chronic Kidney Disease Progression 
We examined whether a clinician’s propensity to act on genetic variants predicting CKD 
progression was associated with their attitude and knowledge of CKD risk variants (Figure 2). 
Respondents were split as to whether the genetic test may alter their dialysis preparation strategies 
(Q5). However, the majority agreed that the presence of two APOL1 risk alleles in a potential donor 
would impact the decision for kidney transplant (Q7). Of those who agreed and disagreed with 
question 5, the majority of respondents in both groups agreed that patients and their families would 
benefit from understanding their genetic risk factors of CKD (Q3, p = 0.05). Additionally, those who 
disagreed that APOL1 status would impact organ transplant decisions (Q7) were also less likely to 
agree that genes influence CKD progression (Q1, p = 0.002). Despite having knowledge about the 
genetic risk factors of CKD and despite feeling that patients and their families would benefit from 
understanding these factors, some individuals were not willing to act on genetic data.  
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2.5. Genetics Predictors of Chronic Kidney Disease Progression
We examined whether a clinician’s propensity to act on genetic variants predicting CKD progression
was associated with their attitude and knowledge of CKD risk variants (Figure 2). Respondents were
split as to whether the genetic test may alter their dialysis preparation strategies (Q5). However, the
majority agreed that the presence of two APOL1 risk alleles in a potential donor would impact the
decision for kidney transplant (Q7). Of those who agreed and disagreed with question 5, the majority of
respondents in both groups agreed that patients and their families would benefit from understanding
their genetic risk factors of CKD (Q3, p = 0.05). Additionally, those who disagreed that APOL1 status
would impact organ transplant decisions (Q7) were also less likely to agree that genes influence CKD
progression (Q1, p = 0.002). Despite having knowledge about the genetic risk factors of CKD and
despite feeling that patients and their families would benefit from understanding these factors, some
individuals were not willing to act on genetic data.
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Figure 2. (A–C) Survey respondents who disagreed that genetic testing affects dialysis preparation 
(Q5) mostly agreed that (A) patients and their families can benefit from understanding the genetic 
contributors of CKD (Q3, p = 0.0473), (B) genetic testing may help them treat their patient’s 
hypertension more effectively (Q18, p = 0.0060), and (C) a genetic profile can influence 
antihypertensive therapeutic response (Q19, p = 0.0041). (D–F) Nearly all of the survey respondents 
who agreed that the presence of two APOL1 risk alleles in a potential donor impacts the decision for 
kidney transplant (Q7) also concurred that (D) a patients genetic profile can influence their risk of 
CKD progression (Q1, p = 0.0020), (E) they review and discuss family histories with every patient they 
meet in the hospital or clinic (Q9, p = 0.0011), and (F) nephrologists should be trained to interpret and 
counsel patients on genetic variants that contribute to CKD (Q12, p = 0.0149). (G–I) Survey 
respondents who disagreed that there is sufficient evidence to implement genetic testing in patients 
Figure 2. (A–C) Survey respondents who disagreed that genetic testing affects dialysis preparation
(Q5) mostly agreed that (A) patients and their families can benefit from understanding the genetic
contributors of CKD (Q3, p= 0.0473), (B) genetic testing may help them treat their patient’s hypertension
more effectively (Q18, p = 0.0060), and (C) a genetic profile can influence antihypertensive therapeutic
response (Q19, p = 0.0041). (D–F) Nearly all of the survey respondents who agreed that the presence
of two APOL1 risk alleles in a potential donor impacts the decision for kidney transplant (Q7) also
concurred that (D) a patients genetic profile can influence their risk of CKD progression (Q1, p = 0.0020),
(E) they review and discuss family histories with every patient they meet in the hospital or clinic
(Q9, p = 0.0011), and (F) nephrologists should be trained to interpret and counsel patients on genetic
variants that contribute to CKD (Q12, p = 0.0149). (G–I) Survey respondents who disagreed that there
is sufficient evidence to implement genetic testing in patients with CKD (Q14) were split approximately
Life 2020, 10, 32 9 of 14
halfway on whether they agreed or disagreed that (G) genetic testing of CKD patients may affect
therapeutic management (Q4, p = 0.0050), (H) genetic testing for CKD provides information that will
help delay or halt CKD progression (Q6, p = 0.0138), and (I) the presence of two APOL1 risk alleles
would impact FSGS management (Q8, p = 0.0052). Response colors are strongly agree (white), agree
(light gray), neutral (medium gray), disagree (dark gray), and strongly disagree (black).
Using a knowledge question (Q14), we then stratified respondents into those who agreed and
disagreed that there is sufficient evidence to implement genetic testing for CKD. Those who agreed
that there is sufficient evidence were also more likely to agree that genetic testing provides information
that may change the therapeutic management of their CKD patients (Q4, p = 0.005) and were more
likely to agree that genetic testing will help them delay or halt the progression of CKD (Q6, p = 0.01).
In contrast, those who disagreed with question 14 were split as to whether genetic testing might change
their therapeutic management or delay or halt the progression of CKD in their patients. It appears that
the more aware a physician is of evidence that supports genetic testing, the more likely they are to
utilize genetic test results in their clinical practice.
2.6. Genetics Predicting Antihypertensive Response
The final disease condition category of the survey assessed opinions on the use of pharmacogenomics
to guide antihypertensive therapy (Figure 3). The majority of respondents agreed that pharmacogenomic
testing provides information that may change the antihypertensives they prescribe (Q20). Those who
agreed with question 20 were more likely to agree that genetic testing will help them diagnose the cause
of their patient’s CKD more effectively (Q2, p = 0.00004) and were more likely to agree that nephrologists
should be trained in CKD genetic testing interpretation and counseling (Q12, p = 0.004). However, those
who agreed with question 20 were split in response when asked if they felt comfortable discussing genetic
results with patients (Q16, p = 0.02). It appears that clinicians who agree with the potential value of
genetic and pharmacogenomic tests are more likely to act on genetic data regardless of comfort.
with CKD (Q14) were split approximately halfway on whether they agreed or disagreed that (G) 
genetic testing of CKD patients may affect therapeutic management (Q4, p = 0.0050), (H) genetic 
testing for CKD provides information that will help delay or halt CKD progression (Q6, p = 0.0138), 
and (I) the presence of two APOL1 risk alleles would impact FSGS management (Q8, p = 0.0052). 
Response colors are strongly agree (white), agree (light gray), neutral (medium gray), disagree (dark 
gray), and strongly disagree (black). 
Using a knowledge question (Q14), we then stratified respondents into those who agreed and 
disagreed that there is sufficient evidence to implement genetic testing for CKD. Those who agreed 
that there is sufficient evidence were also more likely to agree that genetic testing provides 
information that may change the therapeutic management of their CKD patients (Q4, p = 0.005) and 
were more likely to agree that genetic testing will help them delay or halt the progression of CKD 
(Q6, p = 0.01). In contrast, those who disagreed with question 14 were split as to whether genetic 
testing might change their therapeutic management or delay or halt the progression of CKD in their 
patients. It appears that the more aware a physician is of evidence that supports genetic testing, the 
more likely they are to utilize genetic test results in their clinical practice.  
2.6. Genetics Predicting Antihypertensive Response 
The final disease condition category of the survey assessed opinions on the use of 
pharmacogenomics to guide antihypertensive therapy (Figure 3). The majority of respondents agreed 
that pharmacogenomic testing provides information that may change the antihypertensives they 
prescribe (Q20). Those who agreed with question 20 were more likely to agree that genetic testing 
will help them diagnose the cause of their patient’s CKD more effectively (Q2, p = 0.00004) and were 
more likely to agree that nephrologists should be trained in CKD genetic testing interpretation and 
counseling (Q12, p = 0.004). However, those who agreed with question 20 were split in response when 
asked if they felt comfortable discussing genetic results with patients (Q16, p = 0.02). It appears that 
clinicians who agree with the potential value of genetic and pharmacogenomic tests are more likely 
to act on genetic data regardless of comfort. 
 
Figure 3. (A–C) Survey respondents who agreed that genetic testing of HTN patients provides 
information that may change which antihypertensives are prescribed (Q20) were more likely to agree 
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Individuals who disagreed with question 20 were also more likely to disagree that genetic testing
will help them determine the cause of their patient’s CKD more effectively. However, the majority still
agreed that nephrologists should be trained in genetic testing interpretation and counseling. Despite
personal therapeutic management opinions, it is suggested that the majority of all survey respondents
saw value in a nephrologist’s ability to understand genetic testing data and ability to counsel patients
on those results.
3. Materials and Methods
3.1. Participants
A genetic test was implemented in a multi-hospital system. All clinicians (practicing in nephrology
clinics or nephrology service (N = 94) in the health system) who were approached had eligible patients
and assented to the genotyping of their patients. In total, 76 respondents completed all or part of a
survey about their knowledge, attitude, and willingness to act on genetic test results. The clinicians
were classified as either nephrologists (i.e., nephrologists or academic attendings) or trainees (i.e.,
fellows and residents). Trainees were approached based on their participation in a nephrology service.
The study was approved by the Institutional Review Board of Indiana University (IRB #1705413046).
3.2. The Survey
The survey consisted of 26 questions, 23 of which were opinion based. The remaining three
questions assessed demographics of the respondents. Opinion based responses were graded on
a LIKERT scale (i.e., “strongly disagree”, “disagree”, “neutral”, “agree” “strongly agree”). These
responses were numbered 1, 2, 3, 4, and 5 respectively.
The survey was self-administered and confidential. The survey was sent via email or was
hand delivered in a de-identified envelope to individuals who did not respond electronically [18].
No records of personal data (including email addresses) were saved, however records of completion or
participation refusal were kept to ensure that individuals who refused were not contacted again. The
responses were stored in RedCap, secured, and analyzed in Excel.
4. Analysis
Opinion based questions were divided into three clinical categories: general genetics, CKD risk
genetics, or antihypertensive efficacy genetics. Questions were also divided by discipline: knowledge,
attitude, and action. Of those 23 questions, six were identified as questions of primary interest. Namely,
questions 5, 7, 14, 15, 16, and 20. These questions were selected based on response distribution and
relational p-value significance.
The agree (i.e., “strongly agree” and “agree”) and did not agree (i.e., “strong disagree”, “disagree”,
and “neutral”) responses to the questions of interest were compared to the agree and disagree responses
of the remaining 22 questions in a contingency table [19,20].
5. Statistics
Each contingency table was analyzed via Fisher’s exact test in excel [16]. Additionally, all question
responses were relayed as mean ± standard deviation of agreement.
To compare knowledge, attitude, and action responses, analyses that involved unlike discipline
variables were prioritized for final interpretation (e.g., question 5 is an Action question, therefore
analyses of interest would involve variable questions that are categorized as Attitude or Knowledge).
6. Discussion
Among the individuals queried on their opinions of precision medicine, many were willing to
implement genetic testing in their clinical practice. The majority of respondents agreed that genetic
profiles affect CKD progression and therapeutic drug response. However, the majority also agreed
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that there isn’t enough evidence to implement clinical genetic testing in patients who have CKD,
despite suggesting that they might use a genetic test’s results to change the therapeutic management
of their CKD patients. Additionally, there appears to be a debate on whether genetic testing can halt
or delay CKD progression, which may be influenced by the fact that many believe current research
has not produced enough affirmation that supports the benefits of genetic testing. Alternatively, or
additionally, a perceived lack of therapeutic options that target the genetics of interest could drive the
lack of enthusiasm [21].
Interestingly, the clinicians were in agreement that the benefits of genetic testing outweigh the
risks, and that patients and their families can benefit from understanding the genetic factors of
CKD. Individuals who believe that the benefits outweigh the risks are more willing to use clinical
genetic and pharmacogenomic data. Nonetheless, it appears that more clinicians in our cohort favor
pharmacogenomic testing over genetic testing for CKD risk stratification. When the clinicians were
asked if they would follow the dosing suggestions of a pharmacogenomic test for new antihypertensive
prescriptions, the majority agreed that they would comply.
One barrier contributing to the lack of support in clinical genetic testing is comfort. Many
physicians, regardless of agreement stance towards CKD genetic tests, agreed that they were
uncomfortable speaking with patients about genetic results. Generally, individuals who agreed
that they were comfortable speaking with patients about genetic test results were more likely to agree
that they would utilize the testing data. This may be because they feel confident in their knowledge
about genetic testing, however more research is needed to support this postulation. Some individuals
who are uncomfortable discussing genetic results may feel this way because they don’t see a net benefit
in genetic testing when compared to current diagnostic and therapeutic practices. It has been discussed
that cost and analytic accuracy in genetic tests are perceived barriers that many feel prohibit everyday
clinical use, despite the potential benefits of improved patient treatment [22,23]. Observations, however,
suggest that one way to overcome these barriers is through the education of providers on clinical
genetics [24]. This notion is consistent with the data presented in this survey analysis: individuals
who responded positively to having knowledge of clinical genetics and pharmacogenomics were more
likely to act on the given genetic data.
Specifically, this study highlights that while the use of clinical genetic and pharmacogenomic tests
are popular in other fields, genetic testing for CKD risk stratification has yet to gain broad traction
among nephrologists. In addition, pharmacogenomic testing for antihypertensives, while not currently
endorsed by CPIC or DPWG, is generally supported by clinicians throughout our health care systems.
This is exemplified by the 26 providers who are currently utilizing the panel based genetic testing
method mentioned previously.
Within the field of medicine, momentum is shifting from general reactive-based clinical practices
to precision medicine, defined as personalized treatment based on an individual patient’s disease and
needs [25–27]. Specialty practices outside of nephrology, such as oncology or psychiatry, have been faster
to embrace advances in genome-wide sequencing, big-data analytics, and haplotype analysis [28–30].
Changes in therapeutic management behavior in peer practitioners is often a necessary step to normalize
clinical genomic usage [31]. By observing the amount of willingness nephrologists had to implement
genetic data in the survey, it is indicative that while precision medicine usage is not fully accepted
yet, clinicians were more willing to use pharmacogenomics data, perhaps because of its perceived
therapeutic benefit. Further studies are required to replicate genome-wide association studies and
genotype-based pharmacokinetic studies [32]. For individuals who are still unsure of the net benefits
of genetic testing, personalized pharmacogenomic analysis reports for physicians have shown changes
in clinician perceptions towards utilizing pharmacogenomic services [24]. Personalized reports such
as these are thought to positively influence clinician knowledge.
Our small sample size may limit the study’s ability to represent the general population of practicing
clinicians. A second limitation is the correlative nature of the study (individuals who highly agree
with one question were likely to agree with other similar survey questions). While the positive
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correlation and sub-group analyses have selection bias, these were only exploratory analyses. Our
survey analysis also reflects the institutional biases and views of the authors. These limitations are
counterbalanced by strengths. For example, by designing the survey to reflect some of the common
principles of medical innovation (i.e., Knowledge, Attitude, and Action), a unique way to understand
nephrologist’s current perception status of genetics and pharmacogenomics was introduced. This
study also involved different health systems and locations. This provided a good mix of clinicians in
academic and partly academic settings. Additionally, assessing trainee’s opinions allowed inclusion of
those with contemporary medical training.
Future studies should aim toward randomized control trials for pharmacogenomic methods
and APOL1 testing. This will expand available evidence, and will allow a greater proportion of
clinicians to formulate opinions on the value of genome-based prescribing and diagnosis in kidney care.
In general, the nephrology providers queried were willing to use genetic data, particularly if it pertains
to pharmacogenomics. However, significant barriers were still observed in educational resources and
provider comfort; these limitations may be circumvented over time by increased evidence, education,
and accessibility of/to pharmacogenomics and genetic testing for CKD stratification.
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